The DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.
Molecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment
Open accessAbstract
Programmed cell death (PCD) or apoptosis is a mechanism which is crucial for all multicellular organisms to control cell proliferation and maintain tissue homeostasis as well as eliminate harmful or unnecessary cells from an organism. Defects in the physiological mechanisms of apoptosis may contribute to different human diseases like cancer. Identification of the mechanisms of apoptosis and its effector proteins as well as the genes responsible for apoptosis has provided a new opportunity to discover and develop novel agents that can increase the sensitivity of cancer cells to undergo apoptosis or reset their apoptotic threshold. These novel targeted therapies include those targeting anti-apoptotic Bcl-2 family members, p53, the extrinsic pathway, FLICE-inhibitory protein (c-FLIP), inhibitor of apoptosis (IAP) proteins, and the caspases. In recent years a number of these novel agents have been assessed in preclinical and clinical trials. In this review, we introduce some of the key regulatory molecules that control the apoptotic pathways, extrinsic and intrinsic death receptors, discuss how defects in apoptotic pathways contribute to cancer, and list several agents being developed to target apoptosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Apoptosis and Molecular Targeting Therapy in Cancer
Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., & Sakuragi, N. (2014) · BioMed Research International · doi:10.1155/2014/150845 · Cited by 1,121
RetractedSung, B., Park, B., Yadav, V. R., & Aggarwal, B. B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.090209 · Cited by 123
RetractedApoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics
Kerr, J. F. R., Wyllie, A. H., & Currie, A. R. (1972) · British Journal of Cancer · doi:10.1038/bjc.1972.33 · Cited by 15,725
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
miR-15 and miR-16 induce apoptosis by targeting BCL2
Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., Wojcik, S. E., Aqeilan, R. I., Zupo, S., Dono, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506654102 · Cited by 3,517
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
Zou, H., Henzel, W. J., Liu, X., Lutschg, A., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80501-2 · Cited by 3,145
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Causes and consequences of microRNA dysregulation in cancer
Croce, C. M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2634 · Cited by 2,998
Mediators of endoplasmic reticulum stress-induced apoptosis
Szegezdi, E., Logue, S. E., Gorman, A. M., & Samali, A. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400779 · Cited by 2,345
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108 · cited 1×
“MOMP is most commonly mediated via a variety of proteinmembrane and protein-protein interactions of the B-cell lymphoma 2 protein (BCL-2) family (Chipuk et al., 2004).”
THE MITOCHONDRIAL DEATH/LIFE REGULATOR IN APOPTOSIS AND NECROSIS
Kroemer, G., Dallaporta, B., & Resche-Rigon, M. (1998) · Annual Review of Physiology · doi:10.1146/annurev.physiol.60.1.619 · Cited by 1,963
Endonuclease G is an apoptotic DNase when released from mitochondria
Li, L. Y., Luo, X., & Wang, X. (2001) · Nature · doi:10.1038/35083620 · Cited by 1,787
Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis
Ouyang, L., Shi, Z., Zhao, S., Wang, F. ‐., Zhou, T. ‐., Liu, B., & Bao, J. ‐. (2012) · Cell Proliferation · doi:10.1111/j.1365-2184.2012.00845.x · Cited by 1,452
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,451
Overview of cell death signaling pathways
Jin, Z., & El-Deiry, W. S. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.2.1508 · Cited by 1,326
Green, D. R., & Evan, G. I. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00024-7 · Cited by 1,254
Xiao, C., Srinivasan, L., Calado, D. P., Patterson, H. C., Zhang, B., Wang, J., Henderson, J. M., Kutok, J. L., & Rajewsky, K. (2008) · Nature Immunology · doi:10.1038/ni1575 · Cited by 1,228
IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis
Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J. A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.030 · Cited by 1,218 · cited 2×
“Varfolomeev E. et al. demonstrated that a SMAC mimetic which binds to cIAPs results in c-IAP auto-ubiquitination activity and proteasomal degradation (Varfolomeev et al., 2007).”
Caspases in apoptosis and beyond
Li, J., & Yuan, J. (2008) · Oncogene · doi:10.1038/onc.2008.297 · Cited by 1,090
Is NF-κB a good target for cancer therapy? Hopes and pitfalls
Baud, V., & Karin, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2781 · Cited by 1,061
Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
Kang, M. H., & Reynolds, C. P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0144 · Cited by 1,016
A Unified Model for Apical Caspase Activation
Boatright, K. M., Renatus, M., Scott, F. L., Sperandio, S., Shin, H., Pedersen, I. M., Ricci, J.-E., Edris, W. A., Sutherlin, D. P., Green, D. R., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00051-0 · Cited by 968
Three-Dimensional Structure of the Apoptosome
Acehan, D., Jiang, X., Morgan, D. G., Heuser, J. E., Wang, X., & Akey, C. W. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00442-2 · Cited by 911
Chu, Z.-L., McKinsey, T. A., Liu, L., Gentry, J. J., Malim, M. H., & Ballard, D. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10057 · Cited by 872
Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family
Eckelman, B. P., Salvesen, G. S., & Scott, F. L. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400795 · Cited by 813
NF-κB Signals Induce the Expression of c-FLIP
Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K., & Tschopp, J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.16.5299-5305.2001 · Cited by 813
MiR-15a and miR-16-1 cluster functions in human leukemia
Calin, G. A., Cimmino, A., Fabbri, M., Ferracin, M., Wojcik, S. E., Shimizu, M., Taccioli, C., Zanesi, N., Garzon, R., Aqeilan, R. I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800121105 · Cited by 808
VDAC, a multi-functional mitochondrial protein regulating cell life and death
Shoshan-Barmatz, V., De Pinto, V., Zweckstetter, M., Raviv, Z., Keinan, N., & Arbel, N. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.03.002 · Cited by 782
Life and death by death receptors
Guicciardi, M. E., & Gores, G. J. (2009) · The FASEB Journal · doi:10.1096/fj.08-111005 · Cited by 690
In vivo delivery of miRNAs for cancer therapy: Challenges and strategies
Chen, Y., Gao, D.-Y., & Huang, L. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.009 · Cited by 672
Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario
Chipuk, J. E., Bouchier-Hayes, L., & Green, D. R. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401963 · Cited by 631
Fulda, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24064 · Cited by 615
Autophagy and apoptosis: where do they meet?
Mukhopadhyay, S., Panda, P. K., Sinha, N., Das, D. N., & Bhutia, S. K. (2014) · Apoptosis · doi:10.1007/s10495-014-0967-2 · Cited by 572
Rudin, C. M., Hann, C. L., Garon, E. B., Ribeiro de Oliveira, M., Bonomi, P. D., Camidge, D. R., Chu, Q., Giaccone, G., Khaira, D., Ramalingam, S. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3090 · Cited by 564
c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis
Chang, D. W. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf356 · Cited by 563
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 543
Mirza, A., McGuirk, M., Hockenberry, T. N., Wu, Q., Ashar, H., Black, S., Wen, S. F., Wang, L., Kirschmeier, P., Bishop, W. R., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205353 · Cited by 530
Nakahara, T., Takeuchi, M., Kinoyama, I., Minematsu, T., Shirasuna, K., Matsuhisa, A., Kita, A., Tominaga, F., Yamanaka, K., Kudoh, M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1343 · Cited by 497
Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance
Devarajan, E., Sahin, A. A., Chen, J. S., Krishnamurthy, R. R., Aggarwal, N., Brun, A.-M., Sapino, A., Zhang, F., Sharma, D., Yang, X.-H., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1206044 · Cited by 465
Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444
Heart mitochondria: gates of life and death
Gustafsson, A. B., & Gottlieb, R. A. (2007) · Cardiovascular Research · doi:10.1093/cvr/cvm005 · Cited by 422
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 1×
“…-Malignancies or hormone-refractory prostate cancer (Demma et al., 2010) (Bykov et al., 2005a) (Boeckler et al.,2008) (Bykov et al., 2005b) (Lehmann et al., 2012) c) p53 vaccines: Peptide-based vaccines Dendritic-cell based vaccines Recombinant Virus Facilitate the induction of antitumor…”
Nemunaitis, J. J., Ganly, I., Khuri, F. R., Arseneau, J. C., Kuhn, J., McCarty, T. M., Landers, S., Maples, P. B., Romel, L., Randlev, B., et al. (2000) · PubMed · Cited by 404
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
Apoptosis-Inducing Factor: Structure, Function, and Redox Regulation
Sevrioukova, I. F. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3445 · Cited by 335
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival
Wuillème-Toumi, S., Robillard, N., Gomez, P., Moreau, P., Le Gouill, S., Avet-Loiseau, H., Harousseau, J.-L., Amiot, M., & Bataille, R. (2005) · Leukemia · doi:10.1038/sj.leu.2403784 · Cited by 335
MicroRNA and cancer – focus on apoptosis
Wang, Y., & Lee, C. G. L. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00510.x · Cited by 330
The mitochondrial serine protease HtrA2/Omi: an overview
Vande Walle, L., Lamkanfi, M., & Vandenabeele, P. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402291 · Cited by 320
Apoptotic cell signaling in cancer progression and therapy
Plati, J., Bucur, O., & Khosravi-Far, R. (2011) · Integrative Biology · doi:10.1039/c0ib00144a · Cited by 319
Yang, L. P. H., Cao, Z., Yan, H. M., & Wood, W. C. (2003) · PubMed · Cited by 318
Tolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8898 · Cited by 314
Mitochondrial gateways to cancer
Galluzzi, L., Morselli, E., Kepp, O., Vitale, I., Rigoni, A., Vacchelli, E., Michaud, M., Zischka, H., Castedo, M., & Kroemer, G. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.08.002 · Cited by 300
microRNAs: Master Regulators as Potential Therapeutics in Cancer
Garofalo, M., & Croce, C. M. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100517 · Cited by 291
MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer
Garofalo, M., Quintavalle, C., Di Leva, G., Zanca, C., Romano, G., Taccioli, C., Liu, C. G., Croce, C. M., & Condorelli, G. (2008) · Oncogene · doi:10.1038/onc.2008.6 · Cited by 289
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
Touzeau, C., Dousset, C., Le Gouill, S., Sampath, D., Leverson, J. D., Souers, A. J., Maïga, S., Béné, M. C., Moreau, P., Pellat-Deceunynck, C., et al. (2014) · Leukemia · doi:10.1038/leu.2013.216 · Cited by 289
Apoptosome Structure, Assembly, and Procaspase Activation
Yuan, S., & Akey, C. W. (2013) · Structure · doi:10.1016/j.str.2013.02.024 · Cited by 281
Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
Vaillant, F., Merino, D., Lee, L., Breslin, K., Pal, B., Ritchie, M. E., Smyth, G. K., Christie, M., Phillipson, L. J., Burns, C. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.002 · Cited by 276
Kitada, S., Zapata, J. M., Andreeff, M., & Reed, J. C. (2000) · Blood · doi:10.1182/blood.v96.2.393 · Cited by 264
MicroRNA regulation of core apoptosis pathways in cancer
Lima, R. T., Busacca, S., Almeida, G. M., Gaudino, G., Fennell, D. A., & Vasconcelos, M. H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.11.005 · Cited by 260
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Hong, B., Heuvel, A., Prabhu, V., Zhang, S., & El-Deiry, W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106101412 · Cited by 245
Giaccone, G., Zatloukal, P., Roubec, J., Floor, K., Musil, J., Kuta, M., van Klaveren, R. J., Chaudhary, S., Gunther, A., & Shamsili, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1862 · Cited by 245
Duan, H., Heckman, C. A., & Boxer, L. M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.1608-1619.2005 · Cited by 242
de Almagro, M. C., & Vucic, D. (2012) · PubMed · Cited by 237
A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
Chauhan, D., Velankar, M., Brahmandam, M., Hideshima, T., Podar, K., Richardson, P., Schlossman, R., Ghobrial, I., Raje, N., Munshi, N., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210028 · Cited by 229
Van Poznak, C., Seidman, A. D., Reidenberg, M. M., Moasser, M. M., Sklarin, N., Van Zee, K., Borgen, P., Gollub, M., Bacotti, D., Yao, T.-J., et al. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010686204736 · Cited by 222
Shiau, C.-W., Yang, C.-C., Kulp, S. K., Chen, K.-F., Chen, C.-S., Huang, J.-W., & Chen, C.-S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1677 · Cited by 222
Tagscherer, K. E., Fassl, A., Campos, B., Farhadi, M., Kraemer, A., Böck, B. C., Macher-Goeppinger, S., Radlwimmer, B., Wiestler, O. D., Herold-Mende, C., et al. (2008) · Oncogene · doi:10.1038/onc.2008.259 · Cited by 220
Death receptor signals to the mitochondria
Khosravi-Far, R. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.11.1173 · Cited by 214
Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death
Tajeddine, N., Galluzzi, L., Kepp, O., Hangen, E., Morselli, E., Senovilla, L., Araujo, N., Pinna, G., Larochette, N., Zamzami, N., et al. (2008) · Oncogene · doi:10.1038/onc.2008.63 · Cited by 208
Evasion of Apoptosis as a Cellular Stress Response in Cancer
Fulda, S. (2010) · International Journal of Cell Biology · doi:10.1155/2010/370835 · Cited by 207
Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs
Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 202
c-FLIP inhibits chemotherapy-induced colorectal cancer cell death
Longley, D. B., Wilson, T. R., McEwan, M., Allen, W. L., McDermott, U., Galligan, L., & Johnston, P. G. (2006) · Oncogene · doi:10.1038/sj.onc.1209122 · Cited by 202
Chi, K. N., Gleave, M. E., Klasa, R. J., Murray, N., Bryce, C. J., de Menezes, D. E. L., D’Aloisio, S., & Tolcher, A. W. (2001) · PubMed · Cited by 191
Hotte, S. J., Hirte, H. W., Chen, E. X., Siu, L. L., Le, L. H., Corey, A., Iacobucci, A., MacLean, M., Lo, L., Fox, N. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1416 · Cited by 190
VDAC1: from structure to cancer therapy
Shoshan-Barmatz, V., & Mizrachi, D. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00164 · Cited by 189
Levy, O. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.2.159 · Cited by 188
Speetjens, F. M., Kuppen, P. J. K., Welters, M. J. P., Essahsah, F., Voet van den Brink, A. M. E. G., Lantrua, M. G. K., Valentijn, A. R. P. M., Oostendorp, J., Fathers, L. M., Nijman, H. W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2227 · Cited by 185
Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Safa, A., Day, T., & Wu, C.-H. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908783497087 · Cited by 184
Tissue Distribution of the Death Ligand TRAIL and Its Receptors
Spierings, D. C., de Vries, E. G., Vellenga, E., van den Heuvel, F. A., Koornstra, J. J., Wesseling, J., Hollema, H., & de Jong, S. (2004) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.3a6112.2004 · Cited by 183
Solution structure of a baculoviral inhibitor of apoptosis (IAP) repeat.
Day, C. L., Hinds, M. G., Norton, R. S., & Vaux, D. L. (1999) · Nature Structural Biology · doi:10.1038/10701 · Cited by 182
Liu, G., Kelly, W. K., Wilding, G., Leopold, L., Brill, K., & Somer, B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2985 · Cited by 181
Cancer therapeutics: Targeting the apoptotic pathway
Khan, K. H., Blanco-Codesido, M., & Molife, L. R. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.12.012 · Cited by 180
Mediation of the antiapoptotic activity of Bcl-xL protein upon interaction with VDAC1 protein
Arbel, N., Ben-Hail, D., & Shoshan-Barmatz, V. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.345918 · Cited by 179
Shirley, S., & Micheau, O. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.10.009 · Cited by 177
Aron, J. L., Parthun, M. R., Marcucci, G., Kitada, S., Mone, A. P., Davis, M. E., Shen, T., Murphy, T., Wickham, J., Kanakry, C., et al. (2003) · Blood · doi:10.1182/blood-2002-12-3794 · Cited by 171
Galligan, L., Longley, D. B., McEwan, M. V., Wilson, T. R., McLaughlin, K. M., & Johnston, P. G. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0262 · Cited by 169
Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy
Safa, A. R., & Pollok, K. E. (2011) · Cancers · doi:10.3390/cancers3021639 · Cited by 167
O'Brien, S., Moore, J. O., Boyd, T. E., Larratt, L. M., Skotnicki, A. B., Koziner, B., Chanan-Khan, A. A., Seymour, J. F., Gribben, J., Itri, L. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.5748 · Cited by 167
Caspases and cancer: mechanisms of inactivation and new treatment modalities.
Philchenkov, A., Zavelevich, M. P., Kroczak, T., & Łoś, M. (2004) · PubMed · Cited by 163
Mutant p53 reactivation by small molecules makes its way to the clinic
Bykov, V. J. N., & Wiman, K. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.017 · Cited by 162
Tolcher, A. W., Quinn, D. I., Ferrari, A. C., Ahmann, F. R., Giaccone, G., Drake, T., Keating, A. T., & Bono, J. S. D. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr353 · Cited by 158
Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M. M., Fox, N. L., Miceli, R. C., Ullrich, S. J., Fisher, G. A., & Tolcher, A. W. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp292 · Cited by 157
Leffers, N., Lambeck, A. J. A., Gooden, M. J. M., Hoogeboom, B. N., Wolf, R., Hamming, I. L. E., Hepkema, B. G., Willemse, P. H. B., Molmans, B. H. W., Hollema, H., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24597 · Cited by 156
Inhibitors of Apoptotic Proteins: New Targets for Anticancer Therapy
Saleem, M., Qadir, M. I., Perveen, N., Ahmad, B., Saleem, U., Irshad, T., & Ahmad, B. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12176 · Cited by 155
IAP proteins as targets for drug development in oncology
Dubrez, L., Berthelet, J., & Glorian, V. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s33375 · Cited by 152
Singh, R., & Saini, N. (2012) · Journal of Cell Science · doi:10.1242/jcs.095976 · Cited by 145
Inhibitor of apoptosis proteins and apoptosis
Wei, Y., Fan, T., & Yu, M. (2008) · Acta Biochimica et Biophysica Sinica · doi:10.1111/j.1745-7270.2008.00407.x · Cited by 143
Cell death and the mitochondria: therapeutic targeting of the BCL ‐2 family‐driven pathway
Roy, M. J., Vom, A., Czabotar, P. E., & Lessène, G. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12431 · Cited by 137
LncRNAs: New Players in Apoptosis Control
Rossi, M. N., & Antonangeli, F. (2014) · International Journal of Cell Biology · doi:10.1155/2014/473857 · Cited by 137
Lucas, D. M., Davis, M. E., Parthun, M. R., Mone, A. P., Kitada, S., Cunningham, K. D., Flax, E. L., Wickham, J., Reed, J. C., Byrd, J. C., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403388 · Cited by 136
MicroRNAs as regulators of death receptors signaling
Garofalo, M., Condorelli, G. L., Croce, C. M., & Condorelli, G. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.105 · Cited by 127
Pathil, A., Armeanu, S., Venturelli, S., Mascagni, P., Weiß, T. S., Gregor, M., Lauer, U. M., & Bitzer, M. (2006) · Hepatology · doi:10.1002/hep.21054 · Cited by 126
Programmed cell death and cancer
Sun, Y., & Zl, P. (2009) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.072629 · Cited by 125
Non‐peptidic small molecule inhibitors against Bcl‐2 for cancer therapy
Azmi, A. S., & Mohammad, R. M. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21567 · Cited by 123
Assembly of the Mitochondrial Apoptosis-induced Channel, MAC
Martinez‐Caballero, S., Dejean, L. M., Kinnally, M., Oh, K. J., Mannella, C. A., & Kinnally, K. W. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806610200 · Cited by 120
Cellular FLICE-inhibitory protein: an attractive therapeutic target?
Micheau, O. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.4.559 · Cited by 118
PERK-dependent regulation of IAP translation during ER stress
Hamanaka, R. B., Bobrovnikova-Marjon, E. V., Ji, X., Liebhaber, S. A., & Diehl, J. A. (2008) · Oncogene · doi:10.1038/onc.2008.428 · Cited by 117
Trudel, S., Stewart, A. K., Li, Z., Shu, Y., Liang, S., Trieu, Y., Reece, D. E., Paterson, J., Wang, D., & Wen, X. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1526 · Cited by 116
Albershardt, T. C., Salerni, B. L., Soderquist, R. S., Bates, D. J. P., Pletnev, A. A., Kisselev, A. F., & Eastman, A. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.255828 · Cited by 115
Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function
Wright, C. W., & Duckett, C. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26251 · Cited by 115
Svane, I. M., Pedersen, A. E., Johnsen, H. E., Nielsen, D. L., Kamby, C., Gaarsdal, E., Nikolajsen, K., Buus, S., & Claësson, M. H. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0493-5 · Cited by 114
Targeted therapy against Bcl-2-related proteins in breast cancer cells
Emi, M., Kim, R., Tanabe, K., Uchida, Y., & Toge, T. (2005) · Breast Cancer Research · doi:10.1186/bcr1323 · Cited by 114
Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis
Sun, H., Kapuria, V., Peterson, L. F., Fang, D., Bornmann, W. G., Bartholomeusz, G. A., Talpaz, M., & Donato, N. J. (2011) · Blood · doi:10.1182/blood-2010-03-276477 · Cited by 112
Svane, I. M., Pedersen, A. E., Johansen, J. S., Johnsen, H. E., Nielsen, D. L., Kamby, C., Ottesen, S., Balslev, E., Gaarsdal, E., Nikolajsen, K., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0293-4 · Cited by 110
Travert, M., Amé-Thomas, P., Pangault, C., Morizot, A., Micheau, O., Sémana, G., Lamy, T., Fest, T., Tarte, K., & Guillaudeux, T. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.2.1001 · Cited by 107
Fulda, S., & Debatin, K. (2006) · Oncogene · doi:10.1038/sj.onc.1209518 · Cited by 107
Demma, M. J., Maxwell, E., Ramos, R., Liang, L., Li, C., Hesk, D., Rossman, R. R., Mallams, A. K., Doll, R. J., Liu, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.083469 · Cited by 107
Fulda, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0227 · Cited by 107
Kerr, E. M., Holohan, C., McLaughlin, K. M., Majkut, J., Dolan, S., Redmond, K. M., Riley, J. S., McLaughlin, K. M., Stasik, I., Crudden, M. T. C. M., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.8 · Cited by 106
Watanabe, K., Okamoto, K., & Yonehara, S. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401507 · Cited by 102
Inhibitor of apoptosis proteins and apoptosis
Yunbo, Wei, Tingjun, et al. (2008) · 生物化学与生物物理学报:英文版 · Cited by 102
Smac Mimetic Increases Chemotherapy Response and Improves Survival in Mice with Pancreatic Cancer
Dineen, S. P., Roland, C. L., Greer, R. M., Carbon, J. G., Toombs, J. E., Gupta, P. K., Bardeesy, N. M., Sun, H., Williams, N. S., Minna, J. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3892 · Cited by 98
Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis
Iancu-Rubin, C., Mosoyan, G., Glenn, K., Gordon, R. E., Nichols, G. L., & Hoffman, R. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2013.11.012 · Cited by 90
Structural insights into the transcription-independent apoptotic pathway of p53
Chi, S. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.3.261 · Cited by 87
Tanioka, M., Nokihara, H., Yamamoto, N., Yamada, Y., Yamada, K., Goto, Y., Fujimoto, T., Sekiguchi, R., Uenaka, K., Callies, S., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1506-7 · Cited by 86
Mawji, I. A., Simpson, C. D., Hurren, R., Gronda, M., Williams, M. A., Filmus, J., Jonkman, J. E. N., Costa, R. S. D., Wilson, B. C., Thomas, M. P., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk182 · Cited by 86
Bortezomib Combination Therapy in Multiple Myeloma
Kapoor, P., Ramakrishnan, V. G., & Rajkumar, S. V. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.04.010 · Cited by 85
Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study
Reesink‐Peters, N., Hougardy, B. M. T., van den Heuvel, F. A. J., ten Hoor, K. A., Hollema, H., Boezen, H. M., de Vries, E. G. E., de Jong, S., & van der Zee, A. G. J. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.10.046 · Cited by 84
Cisplatin Induces p53-Dependent FLICE-Like Inhibitory Protein Ubiquitination in Ovarian Cancer Cells
Abedini, M. R., Muller, É., Brun, J., Bergeron, R., Gray, D. A., & Tsang, B. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0673 · Cited by 83
Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML)
Bose, P., & Grant, S. (2013) · Leukemia Research Reports · doi:10.1016/j.lrr.2012.11.006 · Cited by 80
Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer.
Weyhenmeyer, B., Murphy, Á. C., Prehn, J. H. M., & Murphy, B. M. (2012) · PubMed · Cited by 79
Prezma, T., Shteinfer‐Kuzmine, A., Admoni, L., Raviv, Z., Sela, I., Levi, I., & Shoshan‐Barmatz, V. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.316 · Cited by 78
Mawji, I. A., Simpson, C. D., Gronda, M., Williams, M. A., Hurren, R., Henderson, C. J., Datti, A., Wrana, J. L., & Schimmer, A. D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1687 · Cited by 78
木下, 博., Yoshikawa, H., Shiiki, K., Hamada, Y., Nakajima, Y., & Tasaka, K. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001215)88:6<986::aid-ijc23>3.0.co;2-b · Cited by 77
Tchoghandjian, A., Jennewein, C., Eckhardt, I., Rajalingam, K., & Fulda, S. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.70 · Cited by 75
Sensitization of human colon cancer cells to TRAIL-mediated apoptosis
Hernandez, A., Wang, Q., Schwartz, S. A., & Evers, B. M. (2001) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(01)80014-7 · Cited by 74
Wu, H.-H., Wu, J., Cheng, Y., Chen, C.-Y., Lee, M.-C., Goan, Y.-G., & Lee, H. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0020 · Cited by 74
Riley, J. S., Hutchinson, R. A., McArt, D. G., Crawford, N., Holohan, C., Paul, I., Schaeybroeck, S. V., Salto‐Tellez, M., Johnston, P. G., Fennell, D. A., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.481 · Cited by 73
Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics
Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_2 · Cited by 72
Dai, Y., Liu, M., Tang, W., Li, Y., Lian, J., Lawrence, T. S., & Xu, L. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-392 · Cited by 72
Lü, J., McEachern, D., Sun, H., Bai, L., Peng, Y., Qiu, S., Miller, R. S., Liao, J., Han, Y., Liu, M., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0864 · Cited by 72
Allegra, D., Bilan, V., Garding, A., Döhner, H., Stilgenbauer, S., Kuchenbauer, F., Mertens, D., & Zucknick, M. (2013) · Leukemia · doi:10.1038/leu.2013.246 · Cited by 71
Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer
Feng, W., Zhang, B., Cai, D., & Zou, X. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.012 · Cited by 70
Cancer gene therapy using a pro-apoptotic gene, caspase-3
Yamabe, K., Shimizu, S., Ito, T., Yoshioka, Y., Nomura, M., Narita, M., Saito, I., Kanegae, Y., & Matsuda, H. (1999) · Gene Therapy · doi:10.1038/sj.gt.3301041 · Cited by 68
Schimmer, A. D., Thomas, M. P., Hurren, R., Gronda, M., Pellecchia, M., Pond, G. R., Konopleva, M. Y., Gurfinkel, D., Mawji, I. A., Brown, E. R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1061 · Cited by 67
Pei, X., Dai, Y., & Grant, S. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1513.3.12 · Cited by 66
Tabernero, J., Dirix, L., Schöffski, P., Cervantes, A., Lopez-Martin, J. A., Capdevila, J., van Beijsterveldt, L., Platero, S., Hall, B., Yuan, Z., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1101 · Cited by 64
Hu, Q., Wu, D., Chen, W., Zhen, Y., & Shi, Y. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.441568 · Cited by 64
Carter, B. Z., Mak, D. H. F., Morris, S. J., Borthakur, G. M., Estey, E. H., Byrd, A. L., Konopleva, M. Y., Kantarjian, H. M., & Andreeff, M. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0545-1 · Cited by 62
Wacheck, V., Heere‐Ress, E., Halaschek-Wiener, J., Lucas, T., Meyer, H., Eichler, H., & Jansen, B. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100251 · Cited by 61
Greer, R. M., Peyton, M., Larsen, J. E., Girard, L., Xie, Y., Gazdar, A. F., Harran, P. G., Wang, L., Brekken, R. A., Wang, X., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3947 · Cited by 61
Emerging Biological Treatments for Uterine Cervical Carcinoma
Vici, P., Mariani, L., Pizzuti, L., Sergi, D., Lauro, L. D., Vizza, E., Tomao, F., Tomao, S., Mancini, E., Vincenzoni, C., et al. (2014) · Journal of Cancer · doi:10.7150/jca.7963 · Cited by 60
Min, K.-J., Seo, B. R., Bae, Y. C., Yoo, Y. H., & Kwon, T. K. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.35 · Cited by 60
Dai, Y., Liu, M., Tang, W., DeSano, J. T., Burstein, E., Davis, M. A., Pienta, K. J., Lawrence, T. S., & Xu, L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0188 · Cited by 59
Chatterjee, D., Schmitz, I., Krueger, A., Yeung, K. C., Kirchhoff, S., Krammer, P. H., Peter, M. E., Wyche, J. H., & Pantazis, P. (2001) · PubMed · Cited by 58
Kuball, J. H. E., Schüler, M., Ferreira, E. A., Herr, W., Neumann, M., Obenauer-Kutner, L. J., Westreich, L., Huber, C. G., Wölfel, T., & Theobald, M. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301709 · Cited by 58
Detachment-induced upregulation of XIAP and cIAP2 delays anoikis of intestinal epithelial cells
Liu, Z., Li, H., Wu, X., Yoo, B. H., Yan, S. R., Stadnyk, A. W., Sasazuki, T., Shirasawa, S., LaCasse, E. C., Korneluk, R. G., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209753 · Cited by 56
The viral death effector Apoptin reveals tumor-specific processes
Rohn, J. L., & Noteborn, M. H. M. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000025808.48885.9c · Cited by 56
ras Oncogene Triggers Up-regulation of cIAP2 and XIAP in Intestinal Epithelial Cells
Liu, Z., Li, H., Derouet, M. F., Filmus, J., LaCasse, E. C., Korneluk, R. G., Kerbel, R. S., & Rosen, K. V. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503724200 · Cited by 54
Song, J. H., Song, D. K., Herlyn, M., Petruk, K. C., & Hao, C. (2003) · PubMed · Cited by 53
Atencio, I. A., Grace, M. J., Bordens, R., Fritz, M. A., Horowitz, J. A., Hutchins, B., Indelicato, S. R., Jacobs, S., Kolz, K., Maneval, D. C., et al. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700870 · Cited by 52
Immunological and Clinical Effects of Vaccines Targeting p53‐Overexpressing Malignancies
Vermeij, R., Leffers, N., van der Burg, S. H., Melief, C. J. M., Daemen, T., & Nijman, H. W. (2011) · BioMed Research International · doi:10.1155/2011/702146 · Cited by 52
Sharma, S., de Vries, E. G. E., Infante, J. R., Oldenhuis, C. N. A. M., Gietema, J. A., Yang, L., Bilic, S., Parker, K., Goldbrunner, M., Scott, J. W., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9952-9 · Cited by 51
Sodium butyrate-induced DAPK-mediated apoptosis in human gastric cancer cells
Shin, H., Lee, Y. S., & Lee, Y. C. (2011) · Oncology Reports · doi:10.3892/or.2011.1585 · Cited by 50
Menon, A. G., Kuppen, P. J. K., van der Burg, S. H., Offringa, R., Bonnet, M.-C., Harinck, B. I. J., Tollenaar, R. A. �. �., Redeker, A., Putter, H., Moingeon, P. E., et al. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700600 · Cited by 49
Sikic, B. I., Wakelee, H. A., von Mehren, M., Lewis, N. L., Calvert, H., Plummer, E. R., Fox, N. L., Howard, T., Jones, S. F., & Burris, H. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.14006 · Cited by 49
Molecular signaling mechanisms of apoptosis in hereditary non-polyposis colorectal cancer
Hassen, S. I. (2012) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v3.i3.71 · Cited by 48
Venza, I., Visalli, M., Oteri, R., Teti, D. V., & Venza, M. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.05.024 · Cited by 45
Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study
Fong, P., Xue, W.-C., Ngan, H., Chiu, P.-M., Chan, K. Y. K., Tsao, S. W., & Cheung, A. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.028027 · Cited by 43
Rao‐Bindal, K., Koshkina, N. V., Stewart, J., & Kleinerman, E. S. (2013) · Current Cancer Drug Targets · doi:10.2174/1568009611313040005 · Cited by 43
Cyclopeptide Smac mimetics as antagonists of IAP proteins
Sun, H., Liu, L., Lü, J., Qiu, S., Yang, C., Han, Y., & Wang, S. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.114 · Cited by 42
Sosin, A. M., Burger, A. M., Siddiqi, A., Abrams, J., Mohammad, R. M., & Al-Katib, A. M. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-57 · Cited by 42
Liedtke, C., Zschemisch, N., Cohrs, A., Roskams, T., Borlak, J. T., Manns, M. P., & Trautwein, C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.08.007 · Cited by 38
Hawkins, C. J., Silke, J., Verhagen, A. M. W., Foster, R., Ekert, P. G., & Ashley, D. M. (2001) · APOPTOSIS · doi:10.1023/a:1011329917895 · Cited by 37
Survivin antisense compound inhibits proliferation and promotes apoptosis in liver cancer cells
Dai, D.-J. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i2.193 · Cited by 31
The Opposing Roles of Cellular Inhibitor of Apoptosis Proteins in Cancer
Lau, R., & Pratt, M. A. C. (2012) · ISRN Oncology · doi:10.5402/2012/928120 · Cited by 31
Hu, Y., Bebb, G. D., Tan, S., Ng, R., Yan, H., Sartor, J., Mayer, L. D., & Bally, M. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1036 · Cited by 30
Bortezomib restores stroma‐mediated APO2L/TRAIL apoptosis resistance in multiple myeloma
Perez, L. E., Parquet, N., Meads, M. B., Anasetti, C., & Dalton, W. S. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01381.x · Cited by 30
Martín, D. H., Boro, A., & Schäfer, B. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055072 · Cited by 27
Structural insights into the dual-targeting mechanism of Nutlin-3
Shin, J., Ha, J., He, F., Muto, Y., Ryu, K., Yoon, H. S., Kang, S., Park, S. G., Park, B. C., Choi, S., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.02.113 · Cited by 26
Yerbes, R., & López‐Rivas, A. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9597-x · Cited by 26
Leonetti, C., Biroccio, A., D’Angelo, C., Semple, S. C., Scarsella, M., & Zupi, G. (2007) · The Prostate · doi:10.1002/pros.20636 · Cited by 23
FLIP: A flop for execution signals
Subramaniam, K., Hirpara, J. L., Tucker‐Kellogg, L., Tucker‐Kellogg, G., & Pervaiz, S. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.07.005 · Cited by 23
Bijangi‐Vishehsaraei, K., Saadatzadeh, M. R., Huang, S., Murphy, M. P., & Safa, A. R. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0477-7 · Cited by 21
p53 as a drug target in cancer therapy
Chêne, P. (2001) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.11.6.923 · Cited by 20
Grillier‐Vuissoz, I., & Mazerbourg, S. (2012) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.s8-002 · Cited by 18
4-oxo-N-(4-hydroxyphenyl)retinamide: Two Independent Ways to Kill Cancer Cells
Tiberio, P., Cavadini, E., Abolafio, G., Formelli, F., & Appierto, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013362 · Cited by 14
Zhuang, J., Laing, N. M., Oates, M., Lin, K., Johnson, G. G., & Pettitt, A. R. (2014) · Pharmacology Research & Perspectives · doi:10.1002/prp2.81 · Cited by 13
Baron, A. D., O’Bryant, C. L., Choi, Y., Royer‐Joo, S., & Portera, C. C. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.4_suppl.532 · Cited by 12
Shin, J., Ha, J., & Chi, S. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.12.054 · Cited by 10
Cited by
Apoptosis: A Target for Anticancer Therapy
Pfeffer, C., & Singh, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020448 · Cited by 1,542
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
Jan, R., & Chaudhry, G.-E.-S. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.024 · Cited by 899
Chondrocyte Apoptosis in the Pathogenesis of Osteoarthritis
Hwang, H., & Kim, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125943 · Cited by 886
The relation between PI3K/AKT signalling pathway and cancer
Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S., & Baradaran, B. (2019) · Gene · doi:10.1016/j.gene.2019.02.076 · Cited by 651
Self-citationApoptosis (programmed cell death) and its signals - A review
Obeng, E. (2021) · Brazilian Journal of Biology · doi:10.1590/1519-6984.228437 · Cited by 513
Metadata
- Authors
- Goldar, S., Khaniani, M. S., Derakhshan, S. M., & Baradaran, B.
- Venue
- Asian Pacific Journal of Cancer Prevention
- Published
- 2015-04-03
- Volume
- 16
- Issue
- 6
- Pages
- 2129-2144
- ISSN
- 1513-7368 (ISSN-L)
- OpenAlex
- W329007366
- Cited by
- 606
- References
- 194
- FWCI
- 15.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.